title: Drug firms and insurers move to center stage in the cost debate.
authors.forename: Merrill
authors.initials: M
authors.lastname: Goozner
mesh_terms: D003363:Cost Control; D016527:Drug Costs; D004345:Drug Industry; D007356:Insurance, Pharmaceutical Services; D014481:United States